News | July 31, 2025
Imfinzi granted Priority Review and Breakthrough Therapy Designation in US
For patients with resectable early-stage gastric and gastroesophageal junction cancers
For patients with resectable early-stage gastric and gastroesophageal junction cancers
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Subscribe To Our Newsletter & Stay Updated
